

IN THE CLAIMS

Please cancel claims 1-20.

Please add new claims 21-42 as detailed below.

Claims 1-7 (canceled)

Claim 8 (withdrawn) The method of Claim 1, wherein said administering is an antagonist of MIP-3 $\alpha$ .

Claim 9 (withdrawn) The method of Claim 8, wherein said antagonist is selected from:

- a) a mutein of natural MIP-3 $\alpha$ ;
- b) an antibody which neutralizes MIP-3 $\alpha$ ; or
- c) an antibody which binds to CCR6.

Claim 10 (withdrawn) The method of Claim 8, wherein said mammal is subject to a skin condition, including one selected from cancer, cancer metastasis, autoimmunity, inflammation, infection, psoriasis, skin transplant, or skin graft.

Claim 11 (withdrawn) The method of Claim 8, wherein said antagonist is administered in combination with an antibiotic, antifungal, antiviral, cancer therapy, or analgesic.

Claim 12 (withdrawn) The method of Claim 8, wherein said antagonist is administered in combination with an immune suppressive therapeutic, anti-inflammatory drug, growth factor, or immune adjuvant.

Claim 13 (withdrawn) The method of Claim 1, wherein said administering is with a primate MIP-3 $\alpha$ .

Claim 14 (withdrawn) The method of Claim 13, wherein said modulating is attracting said cell.

Claim 15 (withdrawn) The method of Claim 14, wherein said cell is attracted to a site of cutaneous lesion.

Claim 16 (withdrawn) The method of Claim 13, wherein said primate MIP-3 $\alpha$  is administered in combination with an antibiotic, antifungal, antiviral, or analgesic.

Claim 17 (withdrawn) The method of Claim 13, wherein said MIP-3 $\alpha$  is administered in combination with a vasodilator, growth factor, cytokine, anti-inflammatory drug, or immune adjuvant.

Claim 18 (withdrawn) A method of purifying a population of cells, said method comprising contacting said cells with MIP-3 $\alpha$ , thereby resulting in the identification of cells expressing a receptor for said MIP-3 $\alpha$ .

Claim 19 (withdrawn) The method of Claim 18, wherein:

- a) said receptor is CCR6; or
- b) said contacting results in specific migration of said cells to a site for purification.

Claim 20 (withdrawn) The method of Claim 18, wherein said migration is through pores of a membrane.

Claim 21 (previously presented Claim 1, in part) A method for modulating migration of a lymphoid cell or a myeloid cell within or to the skin of a mammal suffering from inflammation, said method comprising administering to said mammal an effective amount of an antibody to CCR6, wherein said CCR6 is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 8, said amino acid sequence being without a signal sequence, whereby administration of said antibody ameliorates inflammation.

Claim 22 (previously presented Claim 2) The method of Claim 21, wherein said migration is within said skin.

Claim 23 (previously presented Claim 3) The method of Claim 22, wherein said migration is chemotactic or chemokinetic.

Claim 24 (previously presented Claim 4) The method of Claim 21, wherein said administering is systemic, local, topical, subcutaneous, intracutaneous, or transdermal.

Claim 25 (previously presented Claim 5, in part) The method of Claim 21, wherein said lymphoid cell is a B cell.

Claim 26 (previously presented Claim 5, in part) The method of Claim 21, wherein said lymphoid cell is a T cell.

Claim 27 (previously presented Claim 7) The method of Claim 21, wherein said lymphoid cell or said myeloid cell migrates into the dermal and/or epidermal layers of said skin.

Claim 28 (new) The method of Claim 21, wherein said antibody is administered in combination with an analgesic.

Claim 29 (new) The method of Claim 21, wherein said antibody is administered in combination with an anti-inflammatory drug.

Claim 30 (previously presented Claim 5, in part) The method of Claim 21, wherein said myeloid cell is a dendritic cell.

Claim 31 (previously presented Claim 5, in part) The method of Claim 21, wherein said myeloid cell is a dendritic cell precursor.

Claim 32 (new) The method of Claim 21, wherein said antibody is administered in combination with an antibiotic.

Claim 33 (new) The method of Claim 21, wherein said antibody is administered in combination with an antifungal agent.

Claim 34 (new) The method of Claim 21, wherein said antibody is administered in combination with an antiviral agent.

Claim 35 (new) The method of Claim 21, wherein said antibody is administered in combination with an immune suppressive therapeutic.

Claim 36 (new) The method of Claim 21, wherein said antibody is administered in combination with a growth factor.

Claim 37 (new) The method of Claim 21, wherein said antibody is administered in combination with an immune adjuvant.

Claim 38 (new) The method of Claim 21, wherein said antibody neutralizes CCR6.

Claim 39 (new) The method of Claim 21, wherein said inflammation is caused by psoriasis.

Claim 40 (new) The method of Claim 21, wherein said inflammation is caused by a microbial or a parasitic infection.

Claim 41 (new) The method of Claim 21, wherein said inflammation is caused by skin transplant.

Claim 42 (new) The method of Claim 21, wherein said inflammation is caused by skin graft.